Abstract
Downregulation of mast cells (MCs) function and/or survival is warranted in allergic inflammation (AI), mastocytosis/MC leukemias and in other inflammatory diseases in which MCs have a central role. Human MCs (hMCs) have been recently shown to express the death receptor (DR) TRAIL and the inhibitory receptors (IRs) CD300a and Siglec-8. TRAIL is the only known DR functional on hMCs, and interestingly its function is upregulated by IgE-dependent MC activation. The newly described IRs, CD300a and Siglec-8, potently downregulate MC activation and survival in vitro and inhibit different IgE-mediated responses in vivo. Therefore a selective targeting of TRAIL and of IRs on MC could be a novel immunopharmacological way to downregulate MC-associated diseases.
Original language | American English |
---|---|
Pages (from-to) | 708-714 |
Number of pages | 7 |
Journal | Current Opinion in Immunology |
Volume | 21 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2009 |
Bibliographical note
Funding Information:F Levi-Schaffer's research is supported by the Aimwell Charitable Trust (UK) and the Israeli Ministry of Health.